Results 11 to 20 of about 30,536 (239)

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Journal for ImmunoTherapy of Cancer, 2021
Background Programmed death-1 (PD-1) blockade monotherapy induced durable remission in a subset of patients with relapsed/refractory classical Hodgkin lymphoma (cHL). We asked whether the anti-PD-1 agent, camrelizumab, combined with the DNA demethylating
Weidong Han, Malcolm Brock, Chunmeng Wang, Liang Dong, Qingming Yang, Meixia Chen, Fengxia Shi, Jiejie Liu   +7 more
doaj   +2 more sources

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia

Therapeutic Advances in Hematology, 2023
Decitabine, a member of the 5-azanucleosides, has a dose-dependent mechanism of action in vitro : termination of DNA replication at high doses, and inhibition of DNA methyltransferase at low doses.
Robert Briski, Guillermo Garcia-Manero, Hagop Kantarjian, Farhad Ravandi   +3 more
doaj   +2 more sources

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [PDF]

New England Journal of Medicine, 2016
et al,, Fronick, C. C., Fulton, R. S., Ley, T. J., Miller, C. A., O\u27Laughlin, M., Petti, A. A., Wartman, L. D., Wilson, R. K.   +8 more
core   +3 more sources

DNA methyltransferase inhibitors in hematological malignancies and solid tumors. [PDF]

Int J Cancer
Abstract Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5‐position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor ...
Wenger V, Garcia-Manero G, Zeiser R, Lübbert M.   +3 more
europepmc   +2 more sources

Decitabine priming increases anti–PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models

Journal of Clinical Investigation, 2023
CD8+ exhausted T cells (Tex) are heterogeneous. PD-1 inhibitors reinvigorate progenitor Tex, which subsequently differentiate into irresponsive terminal Tex. The ability to maintain a capacity for durable proliferation of progenitor Tex is important, but
Xiang Li, Yaru Li, Liang Dong, Yixin Chang, Xingying Zhang, Chunmeng Wang, Meixia Chen, Xiaochen Bo, Hebing Chen, W. Han, J. Nie   +10 more
semanticscholar   +1 more source

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.

Blood, 2023
The challenge of eradicating leukemia for patients with acute myelogenous leukemia (AML) following initial cytoreduction has motivated modern efforts to combine synergistic active modalities including immunotherapy.
L. Penter, Yang Liu, J. Wolff, Lin Yang, Len Taing, Aashna Jhaveri, Jackson Southard, Manishkumar Patel, Nicole Cullen, Kathleen L. Pfaff, Nicoletta Cieri, G. Oliveira, S. Kim-Schulze, S. Ranasinghe, Rebecca Leonard, T. Robertson, E. Morgan, Helen X. Chen, Minkyung H Song, M. Thurin, Shuqiang Li, S. Rodig, C. Cibulskis, S. Gabriel, P. Bachireddy, J. Ritz, H. Streicher, D. Neuberg, F. Hodi, S. Gnjatic, M. Davids, K. Livak, Jennifer Altreuter, F. Michor, R. Soiffer, Jacqueline S. Garcia, Catherine J. Wu   +36 more
semanticscholar   +1 more source

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Cancer, 2021
TP53 mutation (TP53mut) confers an adverse prognosis in acute myeloid leukemia (AML). Venetoclax with hypomethylating agents is a current standard for older patients; however, recent reports suggest that TP53mut confers resistance to venetoclax.
Kunhwa Kim, A. Maiti, S. Loghavi, R. Pourebrahim, T. Kadia, C. Rausch, Ken Furudate, N. Daver, Y. Alvarado, M. Ohanian, K. Sasaki, N. Short, Koichi Takahashi, M. Yilmaz, G. Tang, F. Ravandi, H. Kantarjian, C. Dinardo, M. Konopleva   +18 more
semanticscholar   +1 more source

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia

eJHaem, 2023
Treatment paradigms for acute myeloid leukemia (AML) have evolved at a rapid pace in recent years. The combination of venetoclax with a hypomethylating agent prolonged survival in clinical trials when compared to hypomethylating agent monotherapy ...
I. Bouligny, Graeme F Murray, Michael Doyel, Tilak Patel, Josh Boron, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, C. Venn, N. Wages, S. Grant, Keri R Maher   +13 more
semanticscholar   +1 more source

Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents. [PDF]

Eur J Haematol
ABSTRACT Acute myeloid leukemia (AML) in elderly patients presents a major therapeutic challenge, as many are deemed unfit for intensive chemotherapy due to age, comorbidities, or frailty. Venetoclax in combination with hypomethylating agents (HMA) has emerged as a standard‐of‐care for this population, yet outcomes remain heterogeneous and predictive ...
Vigna E, Bruzzese A, Martino EA, Corsonello A, Caserta S, Labanca C, Mendicino F, Lucia E, Olivito V, Amodio N, Morabito F, Gentile M.   +11 more
europepmc   +2 more sources

Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax

Haematologica, 2023
Despite recent advances in the therapy of diffuse large B-cell lymphoma (DLBCL), many patients are still not cured. Therefore, new therapeutic strategies are needed.
Fen Zhu, J. Crombie, Wei Ni, N. Hoang, Swati Garg, L. Hackett, Stephen J. F. Chong, Mary C Collins, L. Rui, J. Griffin, M. Davids   +10 more
semanticscholar   +1 more source